Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries United Therapeutic (NQ: UTHR ) 363.55 +3.33 (+0.92%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about United Therapeutic < Previous 1 2 3 4 5 6 7 8 9 Next > 7 Undervalued Biotech Stocks to Buy for Big-Time Returns July 01, 2024 The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. Via InvestorPlace Chart Of The Day: United Therapeutics - Drugs For Chronic Illnesses June 28, 2024 United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening... Via Talk Markets UroGen Pharma Stock Earns 91 RS Rating June 27, 2024 UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. Via Investor's Business Daily United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors June 27, 2024 From United Therapeutics Corporation Via Business Wire When you look at NASDAQ:UTHR, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. June 26, 2024 UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. Via Chartmill Deep Dive Into United Therapeutics Stock: Analyst Perspectives (5 Ratings) June 12, 2024 Via Benzinga Expert Ratings For United Therapeutics May 21, 2024 Via Benzinga The Latest Analyst Ratings For United Therapeutics May 02, 2024 Via Benzinga Arcellx Stock Earns Relative Strength Rating Upgrade June 21, 2024 One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. Via Investor's Business Daily The 3 Best Medical Device Stocks to Buy in June 2024 June 20, 2024 Medical devices are at the forefront of the digitalization of medicine. making these the three best medical device stocks to buy. Via InvestorPlace Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 June 20, 2024 Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. Via Investor's Business Daily 10 Health Care Stocks Whale Activity In Today's Session June 19, 2024 Via Benzinga Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans June 14, 2024 Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. Via Investor's Business Daily Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade June 12, 2024 On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. Via Investor's Business Daily Krystal Biotech Stock Sees RS Rating Jump To 91 June 11, 2024 On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88. Via Investor's Business Daily 10 Health Care Stocks With Whale Alerts In Today's Session June 11, 2024 Via Benzinga Halozyme Therapeutics Scores RS Rating Jump To 91 June 07, 2024 On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91. Via Investor's Business Daily For those who appreciate value investing, NASDAQ:UTHR is a compelling option with its solid fundamentals. June 05, 2024 Investors should take notice ofUNITED THERAPEUTICS CORP (NASDAQ:UTHR)—it offers a great deal for the fundamentals it presents. Via Chartmill United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From United Therapeutics Corporation Via Business Wire The 3 Most Undervalued Healthcare Stocks to Buy in June 2024 June 04, 2024 Seeking discounts in relevant places makes sense and there are few arenas more compelling than undervalued healthcare stocks. Via InvestorPlace Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics June 03, 2024 Liquidia stock retook its 50-day line Monday on a U.S. judge's ruling on a patent dispute with fellow biotech company United Therapeutics. Via Investor's Business Daily Topics Intellectual Property Exposures Intellectual Property 7 Biotech Stocks That Could Breathe New Life Into Your Portfolio May 20, 2024 Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. Via InvestorPlace Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating May 16, 2024 On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. Via Investor's Business Daily NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. May 15, 2024 UNITED THERAPEUTICS CORP (NASDAQ:UTHR), an undervalued stock with good fundamentals. Via Chartmill Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating May 14, 2024 On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. Via Investor's Business Daily 3 Biotech Stocks to Double Your Money in the Next 24 Months May 06, 2024 The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. Via InvestorPlace Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity May 01, 2024 United Therapeutics impresses with record-breaking Q1 results. Revenue soars 34% Y/Y to $677.7 million, EPS jumps to $6.17. Tyvaso leads the charge with a 56% revenue surge. Via Benzinga UTHR Stock Earnings: United Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 01, 2024 UTHR stock results show that United Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday May 01, 2024 Via Benzinga United Therapeutics Corporation Reports First Quarter 2024 Financial Results May 01, 2024 From United Therapeutics Corporation Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.